^
    Back
    Association details:
    Biomarker:SESN2 overexpression
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    J Dermatol Sci
    Title:

    Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells

    Published date:
    12/24/2022
    Excerpt:
    Elevated Sestrin2 expression was found in vemurafenib-resistance melanoma cells….Our findings demonstrated the contribution of Sestrin2 to the development of BRAFi resistance and the fact that the combination of mTOR blocker assisted Sestrein2 ablation in eliminating BRAFi resistance of melanoma.
    DOI:
    10.1016/j.jdermsci.2022.12.007
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    J Invest Dermatol
    Title:

    677 Sestrin2 contributes to vemurafenib resistance in braf mutant metastatic melanoma cells by detoxifying intracellular reactive oxygen species

    Published date:
    07/01/2020
    Excerpt:
    In the current study, we first found Sestrin2 was up-regulated in melanoma cells and tissues acquired vemurafenib resistance. Overexpression of Sestrin2 in BRAF mutant melanoma cells significantly shifted the IC50 curve while knockdown of Sestrin2 impaired the viability of vemurafenib-resistant cells in exposure to vemurafenib.
    DOI:
    https://doi.org/10.1016/j.jid.2020.03.689